• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Gender differences in stage-adjusted bladder cancer survival.

作者信息

Mungan N A, Aben K K, Schoenberg M P, Visser O, Coebergh J W, Witjes J A, Kiemeney L A

机构信息

Department of Urology, University Medical Center St. Radboud, Nijmegen, The Netherlands.

出版信息

Urology. 2000 Jun;55(6):876-80. doi: 10.1016/s0090-4295(00)00523-9.

DOI:10.1016/s0090-4295(00)00523-9
PMID:10840099
Abstract

OBJECTIVES

Gender differences have been observed in the prognosis of patients with bladder cancer. It has also been suggested that these differences are caused by a worse stage distribution at diagnosis among women. The purpose of this study was to evaluate whether women with bladder cancer have a worse prognosis even after adjustment for disease stage at first presentation.

METHODS

Data on patients with bladder cancer diagnosed between 1973 and 1996 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States (n = 80,305) were obtained from the National Cancer Institute public domain SEER*Stat 2.0 package. Similar data on patients with bladder cancer diagnosed between 1987 and 1994 and registered by two population-based registries in the Netherlands (n = 1722) were obtained through the Comprehensive Cancer Centers, Amsterdam and South. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men and women within each category of the American Joint Committee on Cancer (SEER data) and TNM (Netherlands data) stage groupings.Results. In the United States, the 5-year relative survival rate of male patients with bladder cancer was calculated to be 79.5% (95% confidence interval 79.0% to 80.0%). Among women, the 5-year relative survival rate was significantly worse: 73.1% (95% confidence interval 72.2% to 74.0%). The male versus female 5-year survival rate among stage groups I, II, III, and IV was 96.5% versus 93.7%, 65.5% versus 59.6%, 58.8% versus 49.6%, and 27.1% versus 15.2%, respectively. The (sparser) data from the Netherlands were less conclusive. Women with Stage II and Stage IV disease fared worse than men but the reverse seemed to be true in Stage I disease.

CONCLUSIONS

Female patients with bladder cancer have a worse prognosis than male patients. It is unlikely that the difference can explained entirely by the more frequent diagnosis of higher stages at first presentation among women.

摘要

相似文献

1
Gender differences in stage-adjusted bladder cancer survival.
Urology. 2000 Jun;55(6):876-80. doi: 10.1016/s0090-4295(00)00523-9.
2
Bladder cancer survival: Women better off in the long run.膀胱癌生存:女性长期预后更好。
Eur J Cancer. 2018 May;95:52-58. doi: 10.1016/j.ejca.2018.03.001. Epub 2018 Apr 7.
3
Bladder cancer survival: Women only fare worse in the first two years after diagnosis.膀胱癌生存率:仅在诊断后的头两年,女性的情况更糟。
Urol Oncol. 2019 Dec;37(12):853-861. doi: 10.1016/j.urolonc.2019.08.001. Epub 2019 Aug 31.
4
Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor.睾丸生殖细胞肿瘤年轻与老年患者在分期及形态学调整生存率方面的差异。
Urology. 2002 Nov;60(5):889-93. doi: 10.1016/s0090-4295(02)01886-1.
5
Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.性别差异对膀胱癌生存的影响:来自日本的基于人群的登记数据。
Int J Urol. 2019 Jun;26(6):649-654. doi: 10.1111/iju.13955. Epub 2019 Mar 27.
6
Survival trends in metastatic bladder cancer in the United States: a population based study.美国转移性膀胱癌的生存趋势:一项基于人群的研究。
J Cancer Res Ther. 2015 Jan-Mar;11(1):124-8. doi: 10.4103/0973-1482.140982.
7
Bladder cancer incidence and survival in the south-eastern part of The Netherlands, 1975-1989.
Eur J Cancer. 1994;30A(8):1134-7. doi: 10.1016/0959-8049(94)90472-3.
8
Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.晚期膀胱癌患者化疗使用情况及生存率的性别差异。
Cancer. 2016 Jul 1;122(13):2012-20. doi: 10.1002/cncr.30029. Epub 2016 May 25.
9
Non-bladder cancer mortality in patients with urothelial cancer of the bladder.膀胱癌患者中非膀胱癌相关死亡率。
Urol Oncol. 2013 Jul;31(5):656-63. doi: 10.1016/j.urolonc.2011.03.005. Epub 2011 May 7.
10
Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: Implications for sex disparities.在医疗保险人群中,尿路感染样症状与膀胱癌预后较差相关:对性别差异的影响。
Int J Urol. 2016 Jan;23(1):42-7. doi: 10.1111/iju.12959. Epub 2015 Oct 6.

引用本文的文献

1
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.蛋白质基因组学特征揭示了与肌肉浸润性膀胱癌化疗耐药相关的生物标志物。
Cell Rep Med. 2025 Aug 19;6(8):102255. doi: 10.1016/j.xcrm.2025.102255. Epub 2025 Jul 31.
2
Sex differences in bladder cancer: understanding biological and clinical implications.膀胱癌中的性别差异:理解生物学和临床意义。
Biol Sex Differ. 2025 May 13;16(1):31. doi: 10.1186/s13293-025-00715-6.
3
Unveiling trends in urinary tract cancer mortality among older adults in the United States (1999-2022): a CDC WONDER perspective.
揭示美国老年人泌尿系统癌症死亡率趋势(1999 - 2022年):疾控中心WONDER视角
Int Urol Nephrol. 2025 Apr 5. doi: 10.1007/s11255-025-04490-6.
4
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.性别作为帕博利珠单抗治疗晚期尿路上皮癌患者生存情况的修饰因素
Sci Rep. 2025 Mar 14;15(1):8815. doi: 10.1038/s41598-025-93094-2.
5
Functional Outcomes of Orthotopic Neobladder in Women.女性原位新膀胱的功能结局。
Curr Urol Rep. 2024 Nov;25(11):277-285. doi: 10.1007/s11934-024-01223-7. Epub 2024 Aug 28.
6
Respiratory Complications after Cystectomy with Urinary Diversion: Avoidable Complications or Ineluctable Destiny?膀胱切除术后尿流改道的呼吸并发症:可避免的并发症还是不可避免的命运?
J Clin Med. 2024 Mar 10;13(6):1585. doi: 10.3390/jcm13061585.
7
Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation.建立和验证列线图预测非转移性膀胱癌患者总生存和癌症特异性生存:一项大型基于人群的队列研究和外部验证。
Medicine (Baltimore). 2024 Mar 15;103(11):e37492. doi: 10.1097/MD.0000000000037492.
8
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.膀胱癌中的性别二态性:病因、生物学、诊断及预后综述
Front Pharmacol. 2024 Jan 12;14:1326627. doi: 10.3389/fphar.2023.1326627. eCollection 2023.
9
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States.美国膀胱癌特异性死亡率趋势的纵向分析。
Bladder Cancer. 2023 Dec 13;9(4):345-353. doi: 10.3233/BLC-230062. eCollection 2023.
10
Nomograms for predicting the overall and cancer-specific survival in patients with non-urothelial carcinoma of the bladder: A population-based study.预测非尿路上皮膀胱癌患者总生存和癌症特异性生存的列线图:一项基于人群的研究。
Biomol Biomed. 2024 May 2;24(3):633-646. doi: 10.17305/bb.2023.9881.